Skip to content

Use of Viscoelastic Tests in the Treatment of Traumatic Induced Coagulopathy: a Pragmatic Randomized Clinical Trial.

Use of Viscoelastic Tests in the Treatment of Trauma-induced Coagulopathy: a Pragmatic Randomized Clinical Trial Comparing Viscoelastic Tests With Conventional Assays.

Status
Withdrawn
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03380767
Acronym
VISCOTRAUMA
Enrollment
0
Registered
2017-12-21
Start date
2019-12-31
Completion date
2021-09-30
Last updated
2021-03-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coagulopathy, Massive Hemorrhage, Trauma, Multiple

Keywords

trauma-induced coagulopathy

Brief summary

Trauma is the leading cause of death in young people. Trauma-induced coagulopathy (TIC) encompasses several aspects of traumatic bleeding. Monitoring of coagulopathy comprises use of Point-of-Care (POC) methods, such as thromboelastography (TEG) or Thromboelastometry (ROTEM) and conventional laboratory assays (platelet count, fibrinogen level, and PT or INR). POC tests are thought to have a better performance on mortality and bleeding control than conventional tests. The aim of this study is to compare POC and conventional assays with plasma consumption as a primary outcome and 28 days mortality as a secondary one.

Interventions

PROCEDURETrauma-induced coagulopathy treatment

Transfusion as needed according to the assay methodology

Sponsors

A.O. Ospedale Papa Giovanni XXIII
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

Pragmatic randomized controlled trial

Eligibility

Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
No

Inclusion criteria

all adult (\> 18 years old) trauma patients treated in our Emergency Department with a TASH score \> 18

Exclusion criteria

* dead on arrival * no blood product administered after randomization

Design outcomes

Primary

MeasureTime frameDescription
Fresh frozen plasma consumption3 yearsIn the POC group plasma consumption is estimated 20% less than in conventional assays group

Secondary

MeasureTime frameDescription
Mortality28 days28 days mortality

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026